器官・組織移植及替代技術產品市場

本報告已在2011年08月19日停止出版。

更改為出版

器官・組織的移植以及替代技術產品市場

Organ and Tissue Transplantation and Alternatives

出版日期 : 2011年01月

商品編碼: 208646

簡介

目錄

• Provides full coverage of product segments including solid organs, experimental xenografts and artificial organs, tissue transplants, and cell transplants
• Details forecasts by product type and application through 2010, including supporting analyses for projections
• Overviews international markets
• Discusses the industry' s structure and the regulatory environment
• Profiles leading companies involved, including placement within the market and strategic analyses of available and emerging products.

This report offers forecasts by product segment from 2008 through 2013, including supporting analyses for projections. Product segments covered consist of solid organs (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation market (e.g., bone, skin, cornea, heart valves), along with the pharmaceuticals that accompany each market. Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.

The arrangement of this report offers an overview of the organ and tissue transplantation market accompanied by analyses and forecasts for each product type and application.

International markets are discussed, and information is provided on industry structure and the regulatory environment. Profiles of leading companies involved with tissue transplantation provide information on placement within the market and strategic analyses of the companies' available and emerging products.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.

Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, transplant surgeons, and pertinent societies' and associations' representatives. Additional data was derived from companies' annual reports and 10Ks, journal articles, prospectus assessments, and government resources.

Information for this report was obtained from industry analysts; the Center for Medicare and Medicaid Services (CMS), the National Institutes of Health (NIH), the Centers for Disease Control (CDC) and other government agencies; the United Network for Organ Sharing; the Organ Procurement and Transplantation Network; the Scientific Registry of Transplant Recipients; literature searches; companies' annual reports and 10Ks; and product literature.

Organ and Tissue Transplantation and Alternatives

• SUMMARY 5SUMMARY TABLE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
  • SUMMARY FIGURE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, 2007-2013 ($ MILLIONS)

• INDUSTRY OVERVIEW
• HISTORY OF TRANSPLANTATION
• TISSUE TYPING
• IMMUNOSUPPRESSION
• Newer Immunosuppressive Drugs
• PRESERVATION
• GOVERNMENT REIMBURSEMENT
• THE TRANSPLANTATION PROCESS
• PREPARATION
• SURGERY
• RECUPERATION
• MAINTENANCE
• IMPORTANCE OF THE INDUSTRY
• ORGANS
  • TABLE 1 U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, NUMBER OF PROCEDURES AND VALUE BY TYPE OF ORGAN TRANSPLANT, THROUGH 2013 ($ MILLIONS)
• KIDNEY
  • TABLE 2 LEADING U.S. KIDNEY TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
• LIVER
  • TABLE 3 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• HEART
  • TABLE 4 TOP FIVE U.S. HEART TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• LUNG
  • TABLE 5 TOP FIVE U.S. LUNG TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• INTESTINE
  • TABLE 6 TOP FIVE U.S. INTESTINE/SMALL BOWEL TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• PANCREAS
  • TABLE 7 TOP FIVE U.S. PANCREAS TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• TISSUES
• DRIVERS IN THE MARKET
  • TABLE 8 TISSUE GRAFTING IN THE U.S. BY TISSUE TYPE, THROUGH 2013 (MILLION PROCEDURES)
  • FIGURE 1 U.S. MARKET FOR TISSUE GRAFTING PROCEDURES BY TYPE, 2007-2013 (MILLION PROCEDURES)
• CORNEA
• BLOOD STEM CELLS
• BONE ALLOGRAFTS
• HEART VALVES
• VASCULAR TISSUE
• SKIN AND COLLAGEN
• Applications
• WAITING LISTS OUTPACE DONATIONS
  • TABLE 9 PATIENTS ON U.S. WAITING LISTS AT THE END OF THE YEAR BY TYPE OF ORGAN TRANSPLANT, 2003 - 2006
• TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS
  • TABLE 10 TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS, THROUGH 2013
• TRENDS IN TRANSPLANTATION OF ALL ORGANS
  • TABLE 11 U.S. ORGAN TRANSPLANTS, THROUGH 2006 (NUMBER OF PROCEDURES)
• INTERNATIONAL TRENDS
  • TABLE 12 NUMBERS OF DONATED CADAVERS BY REGION, 2003 - 2006
• LIMITED SUPPLY CURTAILS TRANSPLANTATIONS
• Living Donor Programs
• KEY FACTORS IN INDUSTRY GROWTH
• Reducing Demand
• Patient Survival Rates
  • TABLE 13 ONE-YEAR AND FIVE-YEAR PATIENT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997 - 2004 (%)
  • TABLE 14 ONE-YEAR AND FIVE-YEAR GRAFT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997 - 2004 (%)
  • TABLE 14 (CONTINUED)
  • TABLE 15 NUMBER OF PEOPLE IN THE U.S. LIVING WITH A FUNCTIONING TRANSPLANT BY TYPE, 2000 - 2005*
• Organ Substitutes
• Organs from Animals: Xenotransplantation
• Organ Primordia
• Nuclear Transfer to Eliminate the Rejection Gene
• Porcine Endogenous Retrovirus
• ARTIFICIAL ORGANS
• CELLULAR TRANSPLANTS
• KEY FACTORS INHIBITING GROWTH
• LACK OF DONORS
• ALTERNATIVE THERAPIES
• CULTURAL STIGMAS

• GOVERNMENT REGULATIONS
• THE MEDICARE DRUG DISCOUNT CARD PROGRAM, MEDICARE DRUG BENEFITS, AND TRANSPLANT PATIENTS
  • TABLE 16 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
  • TABLE 17 MEDICARE IMMUNOSUPPRESIVE DRUG COVERAGE OVERVIEW

• HLA TISSUE TYPING
• THE WORLD MARKET FOR HLA TYPING
  • TABLE 18 WORLD MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
• THE U.S. MARKET FOR HLA TYPING
  • TABLE 19 U.S. MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
• ORGAN PRESERVATION PRODUCTS
  • TABLE 20 PRESERVATION TIME FOR TRANSPLANTED ORGANS (HOURS)
• Custodiol
• Warm Organ Perfusion
• IMMUNOSUPPRESSION
  • TABLE 21 IMMUNOSUPPRESSIVE DRUGS APPROVED IN THE U.S. BY CLASS
• Antibodies
  • TABLE 22 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
  • TABLE 23 COMMONLY USED INTRAVENOUS ANTIBODY IMMUNOSUPPRESIVE DRUGS
  • TABLE 23 (CONTINUED)
• OKT-3
• Zenapax
• Simulect
• Campath/MabCampath
• Polyclonal Antibody Products
• Atgam
• Thymoglobulin
• The Market for Antibody Products to Treat Organ Transplant Rejection
  • TABLE 24 GLOBAL MARKET FOR ANTIBODY PRODUCTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2013 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET FOR ANTIBODY PRODUCTS USED IN ORGAN TRANSPLANTATION, 2007-2013 ($ MILLIONS)
• Antiproliferative Agents
• Azathioprine
• CellCept
• Myfortic
  • TABLE 25 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 3 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS, 2007-2013 ($ MILLIONS)
• Calcineurin Inhibitors
• Tacrolimus
• Cyclosporine
• Generic Cyclosporine
  • TABLE 26 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR CALCINEURIN INHIBITORS, 2007-2013 ($ MILLIONS)
• Source: BCC Research
• M-TOR Inhibitors
• Certican
• Rapamune
  • TABLE 27 GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
• Concern About Generics
  • TABLE 28 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 5 U.S. SALES OF IMMUNOSUPPRESSIVES, BY CATEGORY, THROUGH 2013 ($ MILLIONS)
• IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT
  • TABLE 29 SELECTED IMMUNOSUPPRESSIVE AGENTS IN PHASE 1 OR LATER DEVELOPMENT
  • TABLE 29 (CONTINUED)
• TOLERANCE
• Antisense Therapy
• Costimulation
• Chimerism
• USUAL ANTI-REJECTION DRUG PROTOCOLS
  • TABLE 30 COMMON IMMUNOSUPPRESSIVE REGIMENS
• INDUCTION THERAPY
  • TABLE 31 IMMUNOSUPPRESSANT USE FOR INDUCTION, BY ORGAN IN 2006 (%)
• MAINTENANCE THERAPY
  • TABLE 32 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT DISCHARGE BY ORGAN IN THE U.S., 2006 (%)
  • TABLE 33 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT 1-YEAR POST-TRANSPLANT BY ORGAN IN U.S., 2006 (%)
• REJECTION THERAPY
• Risks Associated with Immunosuppressive Therapy
• Annual Cost of Immunosuppressant Drugs
• The World Market for Immunosuppressant Drug Therapy
  • TABLE 34 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS, THROUGH 2013
  • TABLE 35 GLOBAL SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 6 WORLDWIDE SALES OF IMMUNOSUPPRESSANTS BY CATEGORY, 2007-2013 ($ MILLIONS)
  • TABLE 36 WORLDWIDE SALES OF BRAND NAME IMMUNOSUPPRESSANT DRUGS BY COMPANY, 2006 AND 2007 ($ MILLIONS)
• PRODUCTS
• ADDRESSING INFECTION
• GRAFT-VERSUS-HOST DISEASE
• POST-TRANSPLANT INFECTIONS
• ViroPharma Incorporated
• Cardiovascular Disease
  • TABLE 37 COMMON POST-TRANSPLANT INFECTIONS
  • TABLE 38 TIMELINE FOR POST-TRANSPLANT INFECTION
  • TABLE 39 COMMON POST-TRANSPLANT DRUGS
  • TABLE 40 WORLD MARKET FOR ANTI-INFECTIVES USED FOR TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• POST-TRANSPLANT MONITORING
  • TABLE 41 U.S. MARKET FOR POST-TRANSPLANT MONITORING, THROUGH 2013 ($ MILLIONS)
• Cylex

• INCREASING SUPPLY
• SUPPLY MANAGEMENT
• REDUCING WASTE AND REJECTION
• INCREASING THE HARVEST
  • TABLE 42 RECOVERED ORGANS NOT USED BY TYPE, 2003 - 2006
  • TABLE 43 CONSENTED ORGANS NOT RECOVERED BY TYPE, 2003 - 2006
• BETTER HARVESTING
• DEFINITION OF BRAIN DEATH
• PROTECTING HARVESTED ORGANS
• HORMONAL RESUSCITATION
• NON-HEART-BEATING DONORS
• LESS WASTE
• PRESERVATION
• ORGAN PRESERVATION METHODS
• Rinse and Preservation Solutions
  • TABLE 44 MAJOR ORGAN PRESERVATION SOLUTIONS
• Celsior
• Collins Solution
• Custodiol
• Hypothermosol
• ViaSpan
• Market for Preservation Solutions
  • TABLE 45 NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORK COCKTAIL), THROUGH 2013 ($ MILLIONS)
• Organ Preservation Products in Development
• Human BioSystems
• Trophic Solutions
• Machine Perfusion
• Waters Medical Systems
• TransMedics, Inc.
• FIGHTING REJECTION
  • TABLE 46 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2003 - 2006

• TRANSPLANT CENTERS
  • TABLE 47 LEADING U.S. TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
• TESTING
• Blood Typing
• Tissue Typing
• Panel Reactive Antibodies (PRA)
  • TABLE 48 TISSUE TYPING TECHNOLOGIES
• Advances
  • TABLE 49 SELECTED COMPETITORS IN THE HLA TYPING MARKET
• Plasmapheresis: Transplantation without Matching Antigens
• KIDNEY
• MARKET FOR KIDNEY TRANSPLANTS
  • TABLE 50 U.S. MARKET FOR KIDNEY-ONLY TRANSPLANTATION, THROUGH 2013
• MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANTATION
  • TABLE 51 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLION)
• IMMUNOSUPPRESSION
• Drugs Used for Induction
  • TABLE 52 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN KIDNEY TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 53 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER KIDNEY TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and One-year Post-transplant
  • TABLE 54 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POST-TRANSPLANT FOR KIDNEY TRANSPLANTATION, 2002 - 2005 (%)
• ALTERNATIVES
• Mechanical
• Medical
• Animal
• Cellular
• PANCREAS
• MARKET FOR PANCREAS TRANSPLANTATION
  • TABLE 55 U.S. MARKET FOR PANCREAS TRANSPLANTATION, THROUGH 2013
• WAITING LIST
  • TABLE 56 U.S. PANCREAS WAITING LIST, THROUGH 2013
• IMMUNOSUPPRESSION
  • TABLE 57 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR PANCREAS TRANSPLANT PATIENTS, THROUGH 2013
• Drugs Used for Induction
  • TABLE 58 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN PANCREAS TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 59 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER PANCREAS TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and One-year Post-transplant
  • TABLE 60 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT FOR PANCREAS TRANSPLANTATION, 2002 - 2005 (%)
• PREVALANCE OF DIABETES
• ALTERNATIVES
• HEART
  • TABLE 61 U.S. HEART TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
• SUPPLY
• Cultural Backlash
• Accepting Brain Death is Crucial
• WAITING LISTS
• IMMUNOSUPPRESSION
  • TABLE 62 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART TRANSPLANT PATIENTS, THROUGH 2013
• Drugs Used for Induction
  • TABLE 63 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 64 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART TRANSPLANTATION, 2003 - 2006 (%)
  • TABLE 64 (CONTINUED)
• Drugs Used for Anti-rejection between Discharge and 1-year Post-transplant
  • TABLE 65 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN HEART TRANSPLANTATION, 2002 - 2005
• INDICATIONS
  • TABLE 66 LEADING CAUSES OF HEART FAILURE, 2002 - 2006 (%)
• TISSUE TYPING
• PRESERVATION
• ALTERNATIVES
• LIVER
• HISTORY
• TRANSPLANT STATISTICS
• ORGAN RECOVERY
• THE MARKET FOR LIVER TRANSPLANTATION
  • TABLE 67 U.S. LIVER TRANSPLANT MARKET, FIRST YEAR, THROUGH 2013 ($ MILLIONS)
• DONORS
• WAITING LISTS
  • TABLE 68 REGIONAL GROWTH IN LIVER WAITING LISTS, THROUGH 2013
• IMMUNOSUPPRESSION
• Drugs Used for Induction
  • TABLE 69 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LIVER TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 70 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LIVER TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-transplant
  • TABLE 71 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT FOR LIVER TRANSPLANTATION, 2002 - 2005 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 72 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT FOR LIVER TRANSPLANTATION, 2002 - 2005 (%)
  • TABLE 72 (CONTINUED)
• The Market for Immunosuppressive Drugs in Liver Transplantation
  • TABLE 73 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LIVER TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• INDICATIONS
• Causes of Cirrhosis
• TISSUE TYPING
• ORGAN REJECTION
  • TABLE 74 LIVER TRANSPLANT SURVIVAL RATES IN THE U.S. AND EUROPE, 2003 (%)
• LUNGS
• TRANSPLANTATION STATISTICS
• THE MARKET FOR LUNG TRANSPLANTATION
  • TABLE 75 U.S. LUNG TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
• WAITING LISTS
• INDICATIONS
  • TABLE 76 LEADING CAUSES OF CHRONIC LUNG FAILURE IN THE U.S., 2002 - 2006 (%)
• DONATION
• IMMUNOSUPPRESSION
  • TABLE 77 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• Drugs Used for Induction
  • TABLE 78 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 79 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LUNG TRANSPLANTATION, 2002 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
  • TABLE 80 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 81 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN LUNG TRANSPLANTATION, 2002 - 2005 (%)
  • TABLE 81 (CONTINUED)
• REJECTION
  • TABLE 82 U.S. LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES* (%)
• ALTERNATIVES
• HEART-LUNG
• THE MARKET FOR HEART-LUNG TRANSPLANTATION
  • TABLE 83 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
• IMMUNOSUPPRESSION
  • TABLE 84 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• Drugs Used for Induction
  • TABLE 85 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART-LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 86 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART-LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
  • TABLE 87 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002 - 2005 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 88 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002 - 2005 (%)
• WAITING LISTS
  • TABLE 89 U.S. HEART-LUNG WAITING LIST TRENDS, THROUGH 2013
• SURVIVAL RATES
  • TABLE 90 U.S. HEART-LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES (%)
• INTESTINE/SMALL BOWEL
• HISTORY
• TRANSPLANT TYPES
• INDICATIONS
  • TABLE 91 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: ADULT PATIENTS
  • TABLE 92 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: PEDIATRIC PATIENTS
• U.S. TRANSPLANTATION STATISTICS
  • TABLE 93 U.S. SMALL BOWEL TRANSPLANTATION TRENDS, THROUGH 2013
• THE MARKET FOR INTESTINE TRANSPLANTATION
  • TABLE 94 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
• COUNTRIES WITH SMALL BOWEL/INTESTINES TRANSPLANT PROGRAMS
  • TABLE 95 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS
• IMMUNOSUPPRESSION
  • TABLE 96 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• Drugs Used for Induction
  • TABLE 97 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN INTESTINE TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 98 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN INTESTINE TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
  • TABLE 99 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN INTESTINE TRANSPLANTATION, 2002 - 2005 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 100 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN INTESTINE TRANSPLANTATION, 2002 - 2005 (%)
  • TABLE 100 (CONTINUED)
• INFECTION PROPHYLAXIS
• ALTERNATIVES

• OVERVIEW
• FEWER DONATIONS DUE TO PUBLIC MISTRUST
• Compensation
• Cosmetic Tissue Usage
• CORNEA
• HISTORY
• GLOBAL ESTIMATES OF VISUAL IMPAIRMENT
• CORNEAL TRANSPLANTS IN THE U.S.
  • TABLE 101 U.S. CORNEAL TRANSPLANT MARKET, THROUGH 2013
• Waiting Lists
• Waiting Lists: Other Countries
• Tissue Testing
• Preservation
• Cryopreservation
• Immunosuppression
• ALTERNATIVES
• BLOOD STEM CELLS
• HISTORY
• First Successful Transplant
• Donor Registry Established
• INDICATIONS
• Cord Blood
• Cord Blood Banking
• PROCEDURE VOLUMES
  • TABLE 102 PROJECTED U.S. HEMATOPOIETIC STEM CELL TRANSPLANT PROCEDURES, THROUGH 2013
• Autologous Versus Allogeneic
• DONORS
  • TABLE 103 BMDW MEMBER HOME COUNTRIES
• Blood Collection in the U.S.
  • TABLE 104 NUMBER OF BONE MARROW DONORS, BY COUNTRY
• WAITING LISTS
• REJECTION
• IMMUNOSUPPRESSION
• Enzo Biochem
• MARKET FOR IMMUNOSUPPRESSANTS IN BLOOD STEM CELL TRANSPLANTS
  • TABLE 105 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG THERAPY FOLLOWING HEMATOPOIETIC TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
• CORD BLOOD
• Increasing the Number of Cord Blood Cells
• BONE GRAFT TRANSPLANTATION
• HISTORY
• GLOBAL BONE GRAFT MARKET
• PROCEDURES
  • TABLE 106 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2013
  • FIGURE 7 U.S. BONE GRAFT PROCEDURES, 2007-2013 ($ MILLIONS)
• Spinal Fusion
• Joint Replacement
• INDICATIONS
• ORTHOPEDIC IMPLANT MARKET
  • TABLE 107 U.S. AND WORLDWIDE ORTHOPEDIC IMPLANT MARKET GROWTH, THROUGH 2013 ($ MILLIONS)
  • TABLE 108 U.S. ORTHOPEDIC IMPLANT MARKET BY NUMBER AND TYPE OF PROCEDURE, THROUGH 2013
• AUTOGRAFTS
• Autografts (Continued)
  • TABLE 109 U.S. AND WORLD VALUES OF THE BONE GRAFTING MARKET, THROUGH 2013 ($ MILLIONS)
• ALLOGRAFTS
• Allografts (Continued)
• Risks Associated with Allografts
• Products
• Base Tissue
• Demineralized Bone Matrix Products
• Machined Implants
• THE ORTHOBIOLOGICS MARKET
  • TABLE 110 GLOBAL ORTHOBIOGICS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
• The Market for Allografted Tissue
  • TABLE 111 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2013 ($ MILLIONS)
  • FIGURE 8 BONE ALLOGRAFT MARKET, THROUGH 2013 ($ MILLIONS)
• BONE GRAFT SUBSTITUTES
  • TABLE 112 COMPARISON OF BONE GRAFT MATERIALS
  • TABLE 113 SUBSTITUTE BONE GRAFT
• FACTOR-BASED BONE GRAFT SUBSTITUTES
• Factor-Based Bone Graft ..... (Continued)
• Bone Morphogenic Proteins (BMPs)
• InductOs
• INFUSE Bone Graft
• OP-1 Implant
• PREVENTING INFECTION
• PRESERVATION
• COMPETITION
• VASCULAR TRANSPLANTATION
• HISTORY
• INDICATIONS
• PROCEDURES
• DONORS
• HEART VALVES
• HEART VALVE ALLOGRAFT MARKET
  • TABLE 114 U.S. HEART VALVE TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
• TISSUE TESTING
• SYNTHETICS
• XENOGRAFTS
• ADVANCES
• Symetis
• Edwards Life Sciences
• BETTER MONITORING
• TISSUE VALVES GAIN POPULARITY
• MAJOR COMPETITORS
• VASCULAR GRAFTS
• Indications
• Waiting List
• Products
• ALTERNATIVES TO VASCULAR TRANSPLANTATION
• SKIN TRANSPLANTATION
  • TABLE 115 U.S. MARKET FOR HUMAN SKIN-BASED PRODUCTS, THROUGH 2013
• HISTORY
• MARKET POTENTIAL
• INDICATIONS
• Burns
• Other Injuries
• Cosmetic Surgery
• Wounds
• Venous Ulcers
  • TABLE 116 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE U.S. OVER-64 POPULATION, THROUGH 2013
• Diabetic Ulcers
  • TABLE 117 ESTIMATED U.S. INCIDENCE OF DIABETIC FOOT ULCERS, THROUGH 2013 (MILLIONS)
• Pressure Ulcers
• Urinary Incontinence and Other Uses
• Collagen Meniscus Implant
• REJECTION
• TISSUE TESTING
• PRESERVATION
• CELLULAR TRANSPLANTATION
• HISTORY
• INDICATIONS
• TYPES OF CELLS
• DONORS
• REJECTION
• GOVERNMENT REGULATIONS
• ALTERNATIVES

• ALTERNATIVES TO CORNEAL TRANSPLANTATION
• SURGICAL
• ARTIFICIAL CORNEAS
• RETINAL TRANSPLANTS
• CELLULAR TRANSPLANTS
• ELECTRONIC IMPLANTS
• ALTERNATIVES TO INTESTINAL TRANSPLANTATION
• MEDICAL
• CELLULAR
• ALTERNATIVES TO PANCREAS TRANSPLANTATION
• MEDICAL
• Islet Cell Transplantation
• Islet Cell Transplantation (Continued)
• Drawbacks
• Cell Encapsulation
• ReNeuron
• Bioartificial Pancreas
• Cerco Medical
• Cultured Stem Cells
• Diminished Need for Transplantation in the Future
• COSTS
• ALTERNATIVES TO HEART TRANSPLANTATION
• MEDICAL
• Fibroblast Growth Factors
• CardioVascular BioTherapeutic, Inc.
• Endovasc, Ltd.
• Gene Therapy
• Naked Plasmid DNA Transfer
• Adenoviral Vectors
• XENOTRANSPLANTATION
• SURGICAL
• Laser Revascularization
• Mitral Valve Repair
• CARDIAC SUPPORT DEVICES
• Passive Support Systems
• MECHANICAL
• REGENERATION INSTEAD OF REPLACEMENT
• Biophan
• MECHANICAL ORGANS
• VAD Market
• VAD costs
  • TABLE 118 GLOBAL MARKET FOR VADS, THROUGH 2013 ($ MILLIONS)
  • TABLE 119 U.S. MARKET FOR VADS USED AS DESTINATION THERAPY, THROUGH 2013 ($ MILLIONS)
• DeBakey LVAS
• HeartMate
• Incor LVAD, Excor VAD
• Novacor
• VAD DEVELOPMENT IN THE U.S.
  • TABLE 120 LEFT VENTRICULAR ASSIST DEVICES IN DEVELOPMENT
• Arrow International
• CardiacAssist
• Jarvik
• Ventracor
• TOTAL ARTIFICIAL HEARTS
• AbioMed
• CardioWest
• OTHER CARDIAC ASSIST DEVICES IN DEVELOPMENT
• CELLULAR THERAPY
• Bioheart
• ALTERNATIVES TO LIVER TRANSPLANTATION
• MEDICAL
• Vertex Pharmaceuticals
• ARTIFICIAL LIVERS
• CHEMICAL/MECHANICAL AND/OR BIOARTIFICIAL LIVERS
  • TABLE 121 INDICATIONS FOR THE BIOARTIFICIAL LIVER
• Chemical/Mechanical.....(Continued)
  • TABLE 122 BIOARTIFICIAL LIVERS IN DEVELOPMENT
• Bioartificial Liver Support System
• ELAD
• Modular Extracorporeal Liver Support (MELS)
• Molecular Adsorption Recycling System (MARS)
• RELATIVE COSTS
• ALTERNATIVES TO LUNG TRANSPLANTATION
• MEDICAL
• SURGICAL
• ALTERNATIVES TO BONE GRAFTS
• MEDICAL
• SYNTHETIC MATERIALS
• Orthovita
• Spine Wave
• ReGen Biologics
• ALTERNATIVES TO VASCULAR TRANSPLANTATION
• ANIMAL
• Stentless Valves
• Calcification
• SURGICAL
• Angioplasty and Stents
• MEDICAL
• MECHANICAL/SYNTHETIC
• ALTERNATIVES TO VASCULAR TRANSPLANTATION
• TISSUE ENGINEERING OF VASCULAR GRAFTS
• GENE THERAPY
• ALTERNATIVES TO SKIN TRANSPLANTATION
• ANIMAL-BASED PRODUCTS
• Biobrane
• OaSIS
• GROWTH FACTORS
• ARTIFICIAL SKIN/SKIN REPLACEMENT PRODUCTS
• AlloDerm
• Apligraf
• Cymetra
• Dermagraft
• Epicel
• Integra Products
• OrCel
• TransCyte
• MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS
  • TABLE 123 MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACMENT PRODUCTS
• THE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS
  • TABLE 124 ESTIMATED WORLDWIDE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
  • TABLE 125 ESTIMATED U.S. MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
• PRODUCTS IN DEVELOPMENT
• Altex Plus, Ltd.
• Cytomedix
• Geron
• OTHER RESEARCH
• REGULATION

• ABIOMED, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ARBIOS SYSTEMS, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ARROW INTERNATIONAL
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ASTELLAS PHARMA, INC
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• CRYOLIFE, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• DEPUY ORTHOPEDICS
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• EDWARDS LIFESCIENCES
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• EXACTECH
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• FORTICELL BIOSCIENCE
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• FRESENIUS MEDICAL CARE AG & CO. KGAA
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• GENZYME
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• HEMOCLEANSE, INC
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• JOHNSON & JOHNSON
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• KIADIS PHARMA
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• KINETIC CONCEPTS, INC. (KCI)
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• LIFEBLOOD MEDICAL, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• LIFECELL CORP. (SEE KINETIC CONCEPTS, INC)
• LIFECYCLE PHARMA A/S
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• LIVING CELL TECHNOLOGIES, LTD.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• MEDTRONIC, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• NOVARTIS AG
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ON-X LIFE TECHNOLGIES, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• ORGANOGENESIS, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• OSTEOTECH
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• PDL BIOPHARMA
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ROCHE PHARMACEUTICALS
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• SORIN GROUP, S.P.A.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• ST. JUDE MEDICAL
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• STRYKER CORPORATION
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• SYNCARDIA SYSTEMS, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• SYTHES (US)
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• TRANSMEDICS, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• THORATEC CORP.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• VENTRACOR
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• VIROPHARMA, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• WORLD HEART CORP.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• WYETH
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS

相關商品

矚目市場調查報告書

全套市場調查報告定期訂閱

Market Research Report Subscription

再生醫學相關市場調查報告書

美國的再生醫療市場
U.S. Tissue Engineering Markets
價格 : US $ 6000
出版日期 : 2012年01月

全球再生醫學·組織再生市場及技術
Tissue Engineering and Regeneration: Technologies and Global Markets
價格 : US $ 4850
出版日期 : 2012年01月

神經幹細胞·前驅細胞產品的策略性開發
Strategic Development of Neural Stem & Progenitor Cell Products
價格 : US $ 3495
出版日期 : 2012年01月

BCC Research發行的生物科技相關市場調查報告書

生物科技市場調査評論：2011年

2011 Biotechnology Research Review

價格 : US $ 850

出版日期 : 2012年01月

合成生物學:新的全球的市場

Synthetic Biology: Emerging Global Markets

價格 : US $ 4850

出版日期 : 2011年11月

免疫測定・基因探針用標識藥劑與結合藥劑

Labeling and Linkage Agents for Immunoassays and Gene Probes

價格 : US $ 4850

出版日期 : 2011年10月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!